Frequently Asked Questions:
- What are NAV-240 and NAV-242?
NAV-240 and NAV-242 are investigational bispecific antibodies from Navigator Medicines targeting both TNFα and OX40L. NAV-242 is a subcutaneous, half-life-extended version designed for less frequent dosing.
- What did the late-breaking HS spatial mapping study show?
Research led by Johannes Griss of the Medical University of Vienna found TNFα and OX40L concentrated near tunnel-associated cells in HS skin, suggesting both pathways contribute to inflammation in draining tunnels.
Tumor necrosis factor alpha (TNFα) and OX40 ligand (OX40L) both cluster near cells surrounding draining tunnels in hidradenitis suppurativa (HS) skin, according to late-breaking spatial mapping data presented at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria. Navigator Medicines, which supported the research, is developing 2 bispecific antibodies designed to block both targets simultaneously.¹
The company also presented early-phase safety data for its lead candidate, NAV-240, and preclinical findings for a longer-acting successor, NAV-242. A phase 2a trial of NAV-240 in HS is enrolling faster than anticipated, according to Navigator.¹
What Did the Spatial Mapping Study Find?
Johannes Griss, MD, PhD, an associate professor at the Medical University of Vienna, led the analysis of skin sections from patients with HS. Both TNFα and OX40L localized close to tunnel-associated cells, implicating the 2 pathways in disease pathology.¹
Griss presented the findings in a late-breaking session on October 1, 2026 (D2T01.4B). In the company's announcement, he said pinpointing where the immune response occurs in HS is essential for designing better therapies. He interpreted the concentration of both molecules at tunnel sites as evidence they work in concert to maintain inflammation, supporting continued investigation of dual-targeting agents.¹
Navigator suggested bispecific antibodies acting on both pathways could reduce inflammation specifically where tunnels form. Draining tunnels, also called sinus tracts or fistulas, develop beneath the skin in more advanced disease and contribute to pain, scarring, and daily burden.¹
What Did Early Data Show for NAV-240 and NAV-242?
A poster (P1749) reported translational data from phase 1 single and multiple ascending dose studies of NAV-240 in 64 healthy volunteers. According to the company, the agent showed acceptable safety and tolerability, low immunogenicity, and pharmacodynamic results consistent with its dual mechanism. Antiviral T-cell function was preserved, which Navigator described as important for long-term immune health.¹